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Olmesartan medoxomil, the angiotensin II receptor 
blocker (ARB), has been widely used to manage cardio-
vascular diseases including hypertension since its ap-
proval in 2002 [1] with estimated worldwide sales of US 
$2 billion in 2009. Rubio-Tapia et al. [2] first described a 
case series of severe sprue-like enteropathy at the Mayo 
Clinic in the United States in 2012, which was linked to 
the use of olmesartan. Similar cases have been reported 
at other locations in the United States, Europe [3], and 
India [4]. A class effect of ARBs was suspected after sever-
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Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker 
(ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associ-
ated enteropathy have been reported in Northeast Asia. We investigated the asso-
ciations between olmesartan and other ARBs and the incidence of enteropathy in 
Korea.
Methods: Our retrospective cohort study used data from the Korean National 
Health Insurance Service to identify 108,559 patients (58,186 females) who were 
initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or 
other ARBs between January 2005 and December 2012. The incidences of enterop-
athy were compared among drug groups. Changes in body weight were compared 
after propensity score matching of patients in the ACEis and olmesartan groups.
Results: Among 108,559 patients, 31 patients were diagnosed with enteropathy. 
The incidences were 0.73, 0.24, and 0.37 per 1,000 persons, in the ACEis, olme-
sartan, and other ARBs groups, respectively. Adjusted rate ratios for enteropathy 
were: olmesartan, 0.33 (95% confidential interval [CI], 0.10 to 1.09; p = 0.070) and 
other ARBs, 0.34 (95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis group af-
ter adjustment for age, sex, income level, and various comorbidities. The post hoc 
analysis with matched cohorts revealed that the proportion of patients with sig-
nificant weight loss did not differ between the ACEis and olmesartan groups.
Conclusions: Olmesartan was not associated with intestinal malabsorption or 
significant body weight loss in the general Korean population. Additional large-
scale prospective studies of the relationship between olmesartan and the inci-
dence of enteropathy in the Asian population are needed.
Keywords: Angiotensin receptor antagonists; Olmesartan; Insurance claim re-
view; Drug-related side effects and adverse reactions; Intestinal diseases
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al case reports of other ARB-associated enteropathy [5,6]. 
In July 2013, the United States Federal Drug Admin-
istration changed the olmesartan medoxomil combina-
tion label to include warnings of sprue-like enteropathy 
[7]. Recently, a French nationwide cohort study found an 
association between olmesartan and the risk of enterop-
athy, using claim data [8]. In April 2016, Agence Nationale 
de Sécurité du Médicament et des Produits de Santé (The 
national agency for the safety of medicines and health 
products) delisted specialties containing olmesartan in 
France because of the risk of sprue-like enteropathy and 
its unproven effectiveness in terms of improving mor-
bidity and mortality related to hypertension.
The prevalence of celiac disease is very low or un-
known in Northeast Asian countries such as Korea, Japan, 
and China [9]. To date, no cases of olmesartan- or other 
ARB-associated sprue-like enteropathy have been report-
ed in Northeast Asia. We investigated the associations of 
olmesartan and other ARBs with enteropathy in Korea. 
We investigated the associations of olmesartan and other 
ARBs with enteropathy in Korea using a large nationwide 
cohort.  We also compared changes in weight, hemoglobin, 
and serum cholesterol levels in patients taking angiotensin 
converting enzyme inhibitors (ACEis) and olmesartan.
METHODS
Data source
The Korean National Health Insurance Service (NHIS) 
was established in 1977 and provided universal cover-
age by 1989 [10]. In 2015, the NHIS released a fully an-
onymized, de-identified National Sample Cohort 2002 
to 2013 database (NHIS-NSC 2002–2013). A systematic 
stratified random sampling strategy with proportional 
allocation in each stratum was used to provide represen-
tative, useful health insurance data. The cohort consist-
ed of 1,025,320 Koreans identified in 2002 and followed 
for 11 years through 2013. The database contains de-
mographic information, diagnoses, prescriptions from 
clinics and/or hospitals, ambulatory healthcare use, hos-
pitalization, and health outcomes such as death for the 
respective years [11].
The NHIS instituted the biennial national health ex-
amination program, which is recommended for all of 
the insured employees or self-employed individuals 
over 40 years old and their dependents. The national 
health examination data include body weight, height, 
hemoglobin, and total cholesterol measurements ob-
tained on the same day after an overnight fast. These 
data are included in the NHIS-NSC 2002 to 2013. We 
could not obtain informed consent from individual par-
ticipants because the dataset was fully anonymized and 
de-identified. Detailed information on the NHIS-NSC 
database has been previously published [11]. Our study 
was performed in accordance with the ethical guidelines 
of the 1975 Declaration of Helsinki, and was approved 
by the Institutional Review Board of Ajou University 
Hospital (AJIRB-MED-EXP17). Because of retrospective 
nature of this study, the informed consent was not re-
quired.
Study population and exposure assessment 
Olmesartan was introduced in Korea in 2005. We enrolled 
NHIS-NSC 2002 to 2013 patients who were prescribed 
ACEis, olmesartan, or other ARBs between January 2005 
and December 2012. All of the patients who started or 
were using ACEis or ARBs between 2002 and 2004 were 
excluded from the study to prevent left censoring. Only 
patients who had observation period more than 1 year 
before initiation of these drugs were included. Further-
more, patients were excluded from the analysis if they 
had been diagnosed with intestinal malabsorption prior 
to the initiation of ACEis or ARBs. Because celiac disease 
is rare in Korea, no established treatment regime exists; 
thus, we could not exclude patients based on treatment 
for this disease. The study sample was divided into 
three groups according to drug exposure (olmesartan, 
other ARBs, or ACEis). Each group was mutually exclu-
sive. Because adverse events may necessitate a change in 
drugs, the olmesartan and other ARBs groups included 
patients who had previously taken ACEis. The period of 
overlapping exposures (e.g., ACEi + olmesartan) was re-
moved from the analysis to prevent misinterpretation of 
the data. Exposure was calculated starting from the date 
a prescription was filled for a drug of interest more than 
7 days. The end of exposure was defined as the end of 
the prescription with an additional 30-day grace period 
to account for incomplete medication adherence and to 
avoid the underestimation of drug exposure or misin-
terpretation of adverse events. 
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Outcome and study covariates
Disease information was classified according to the Ko-
rean Classification of Disease 6 (KCD-6), which is based 
on the 10th revision of the International Classification 
of Diseases 10 (ICD-10) code. The primary outcome was 
diagnosis and treatment for intestinal malabsorption 
(KCD-6 code, K90x). The following comorbidities were 
selected as covariates based on a previous French na-
tionwide study [8]: heart failure, dementia, diabetes mel-
litus (DM), autoimmune diseases (rheumatoid arthritis, 
Hashimoto thyroiditis, IgA deficiency, dermatitis her-
petiformis, systemic lupus erythematosus, Sjogren’s 
syndrome, dermatopolymyositis, complement deficien-
cy, angioedema, and inflammatory bowel diseases), or-
gan transplantation, cancer, and chronic kidney disease 
(CKD). In addition, level of average income, hyperten-
sion and dyslipidemia were also adjusted. Patients with 
autoimmune diseases are prone to develop celiac dis-
ease or other autoimmune diseases. ACEis and ARBs 
are frequently prescribed for DM. Diarrhea, caused by 
diabetic autonomic neuropathy is a common complica-
tion of DM. Heart failure, CKD, cancer, and organ trans-
plantation are serious comorbidities that may have an 
impact on malabsorption and diarrhea. 
Post hoc analysis using a matched cohort
To reduce bias caused by the underdiagnosis of subclin-
ical intestinal malabsorption, we compared the changes 
in body weight, cholesterol, and hemoglobin, and the 
incidence of significant body weight loss defined by an-
nually 5% or more body weight loss [12] in the olmesar-
tan and ACEis groups within those of a matched cohort. 
The R package MatchIt (R Foundation for Statistical 
Computing, Vienna, Austria) was used to generate pro-
pensity scores and match olmesartan and ACEis users 
who underwent general medical examinations 1 year be-
fore drug initiation and while under treatment with the 
drug. Propensity scores, which represent the probability 
of receiving each drug, were used in the logistic regres-
sion analysis [13]. Seventeen covariates were used to gen-
erate the propensity score (age, sex, income level, initial 
examination time, total duration of drug use, differ-
ences in the year of the physical examination, baseline 
systolic blood pressure, fasting blood glucose, total cho-
lesterol, hemoglobin, body mass index [BMI], hyperten-
sion, dyslipidemia, heart failure, chronic kidney disease, 
ongoing cancer, and income level). After the propensity 
scores were generated, the patients in each drug group 
underwent 1:1 nearest neighbor (Greedy-type) matching 
of the logit of the propensity score with a caliper width 
of a 0.05 standard deviation of the score. Matching was 
performed without replacement, and non-matched re-
sults were discarded.  
Statistical analysis
A multivariable logistic regression model was used to 
analyze the incidence of enteropathy associated with 
drug after adjustment for selected comorbidities. The 
means or percentages of baseline characteristics, and 
the results from physical examination between drug 
groups were compared using independent Student t 
tests for continuous variables and the chi-square for 
categorical variables. Statistical tests were conducted us-
ing R version 3.2.5 (R Foundation). All p values were two-




We identified 108,687 patients from the NHIS-NSC 
(2002 to 2013) database who were initiated on ACEis, 
olmesartan, or other ARBs between 2005 and 2012. We 
excluded 128 patients diagnosed with enteropathy prior 
to inclusion in the database. A total of 108,559 patients 
were enrolled in our study, culminating in total obser-
vation period of 1,263,601 person-years (PYs) including 
observation period prior to initiation of the drug. The 
patients were grouped according to drug exposure: 
ACEis, 8,487 patients (females, 45.4%); olmesartan, 23,610 
patients (females, 47.9%); and ARBs, 76,462 patients (fe-
males, 48.4%) (Fig. 1). Patient baseline characteristics are 
shown in Table 1.
Patients of ACEis group were older and had more 
heart failure, dementia, DM, autoimmune disease, or-
gan transplantation, ongoing cancer, and CKD com-
pared to olmesartan group (all p < 0.05). Drug use period 
was longer in olmesartan group than in ACEis group 
(1.60 years vs. 1.50 years, p < 0.001).
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Incidence of enteropathy and risk over time
A total of 31 patients were diagnosed with enteropathy 
during drug use (Table 2). The incidences of enterop-
athy in the ACEis, olmesartan, and other ARBs groups 
were 0.73, 0.24, and 0.37 per 1,000 person, respectively. 
Among patients exposed to a drug for more than 1 year, 
the incidences of enteropathy in the ACEis, olmesar-
tan, and other ARBs groups were 0.99, 0.18, and 0.19 per 
1,000 persons, respectively. The crude odd ratios were 
lower in the olmesartan and other ARBs group than in 
ACEis group (odd ratio [OR], 0.26; 95% confidential in-
terval [CI], 0.08 to 0.80; p = 0.020 in olmesartan group 
and OR, 0.30; 95% CI, 0.13 to 0.72; p = 0.007 in other ARBs 
group) (Table 3). 
Adjusted rate ratios for enteropathy were: olmesartan, 
0.33 (95% CI, 0.10 to 1.09; p = 0.070) and other ARBs, 0.34 
(95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis 
Table 1. Baseline characteristics
Variable ACEi (n = 8,487) Olmesartan (n = 23,610) Other ARBs (n = 76,462) p valuea
Age, yr 62.2 ± 14.3 58.9 ± 13.3 58.9 ± 13.3 < 0.001
Female sex 3,856 (45.4) 11,309 (47.9) 37,021 (48.4) < 0.001
Income level, deciles  5.44 ± 2.73  5.36 ± 2.67  5.42 ± 2.70 0.037
Total observation period, yr 10.8 ± 2.2 11.7 ± 1.1 11.7 ± 1.1 < 0.001
Drug use period, yr 1.50 ± 2.16 1.60 ± 1.82 2.46 ± 2.1 < 0.001
Comorbidity 
Hypertension 6,684 (78.8) 21,882 (92.7) 69,983 (91.5) < 0.001
Dyslipidemia 2,510 (29.6) 7,422 (31.4) 26,565 (34.7) 0.002
Heart failure 875 (10.3) 1,072 (4.5) 3,729 (4.9) < 0.001
Dementia 229 (2.7) 526 (2.2) 1,291 (1.7) 0.016
Diabetes mellitus 2,450 (28.9) 6,176 (26.2) 19,643 (25.7) < 0.001
Autoimmune disease 87 (1.0) 182 (0.8) 787 (1.0) 0.033
Organ transplantation 27 (0.3) 11 (0.0) 76 (0.1) < 0.001
Ongoing cancer 622 (7.3) 611 (2.6) 2,393 (3.1) < 0.001
Chronic kidney disease 76 (0.9) 220 (0.9) 655 (0.9) 0.815
Inclusion year
2005 1,716 (20.2) 1,630 (6.9) 5,680 (7.4)
2006 1,413 (16.6) 2,752 (11.7) 6,180 (8.1)
2007 1,539 (18.1) 3,476 (14.7) 6,442 (8.4)
2008 1,425 (16.8) 3,738 (15.8) 9,387 (12.3)
2009 870 (10.3) 3,020 (12.8) 13,861 (18.1)
2010 534 (6.3) 2,963 (12.5) 11,237 (14.7)
2011 522 (6.2) 3,049 (12.9) 12,738 (16.7)
2012 468 (5.5) 2,982 (12.6) 10,937 (14.3)
 Values are presented as mean ± SD or number (%).
ACEi, angiotensin converting enzyme  inhibitor; ARB, angiotensin receptor blocker.
aThe results from ACEi group and olmesartan group were compared.
108,687 Adult patients initiating olmesartan, other ARBs or
ACEi treatment between 2005 and 2013
128 Diagnosed for enteropathy 
       before intiation of the drug
8,487 ACEi 23,610 Olmesartan 76,462 Non-olmesartan ARB
108,599 Patients indluded
Figure 1. Inclusion f low chart. ACEi, ACE inhibitor; ARB, 
angiotensin receptor blocker.
5You SC, et al. Olmesartan and the risk of enteropathy
www.kjim.orghttps://doi.org/10.3904/kjim.2017.002
group after adjustment age, sex, income level, hyper-
tension, dyslipidemia, heart failure, dementia, DM, au-
toimmune diseases, CKD, organ transplantation, and 
ongoing cancer. Stratification of the patients according 
to duration of drug exposure revealed that the adjust-
ed risk of enteropathy in patients receiving olmesartan 
for more than 1 year was not significantly different from 
that of patients receiving ACEis (OR, 0.25; 95% CI, 0.04 to 
1.62; p = 0.147). Adjusted OR was lower in patients using 
other ARBs more than 1 year than in patients using ACEi 
(OR, 0.24; 95% CI, 0.06 to 0.90; p = 0.034). The risks of en-
teropathy between olmesartan and other ARBs were not 
significantly different, regardless of drug period after 
adjustment for age, sex, and comorbidities (all p > 0.05). 
Differences in clinical parameters and biochemical 
analysis
A total of 3,758 patients underwent medical examinations 
1 year before the initiation of ACEis or olmesartan and 
during drug use. Using propensity score matching, we 
matched 665patients in each drug group. Baseline data 
and changes in clinical and biochemical parameters use 
are shown in Table 4. Age, sex, income level, drug use 
period, follow-up duration, comorbidities, baseline an-
thropometric and biochemical parameters did not dif-
fer within the matched cohorts (all p > 0.05). Baseline 
weight and BMI were 65.8 kg, 24.9 kg/m2 in ACEis group, 
and 66.5 kg, 24.9 kg/m2 in olmesartan group, respectively 
(all p > 0.05). The decrease in body weight per year was 
greater in the ACEis than the olmesartan group (–0.3 kg/
year vs. 0.1 kg/year, respectively; p < 0.001). BMI also de-
Table 2. Risk over time: descriptive data
Variable ACEi Olmesartan ARB
Person
< 1 yr 5,447 12,299 24,014
≥ 1 yr 3,040 11,311 52,448
No. of events
< 1 yr 4 3 9
≥ 1 yr 3 2 10
Incidence per 1,000 persons 
< 1 yr 0.73 0.24 0.37
≥ 1 yr 0.99 0.18 0.19
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.    
Table 3. Crude and adjusted odd ratios of intestinal malabsorption over time (ref: ACEi)
Variable
Crude odd ratio Adjusted odd ratio
Value 95% CI p value Value 95% CI p value
Overall population
Olmesartan 0.26 0.08–0.80 0.020 0.33 0.10–1.09 0.070
Other ARBs 0.33 0.10–1.01 0.070 0.34 0.14–0.83 0.017
Treatment duration < 1 yr
Olmesartan 0.33 0.07–1.48 0.149 0.45 0.09–2.19 0.326
Other ARBs 0.51 0.16–1.66 0.263 0.53 0.16–1.75 0.295
Treatment duration ≥ 1 yr
Olmesartan 0.18 0.03–1.07 0.060 0.25 0.04–1.62 0.147
Other ARBs 0.19 0.05–0.70 0.013 0.24 0.06–0.90 0.034
Adjusted with age, sex, income level, hypertension, dyslipidemia, heart failure, dementia, diabetes mellitus, autoimmune dis-
ease, chronic kidney disease, organ transplantation, and cancer.
ACEi, angiotensin converting enzyme inhibitor; CI, confidence interval; ARB, angiotensin receptor blocker. 
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creased more in ACEi than olmesartan group (–0.1 kg/
m2/year vs. 0.0 kg/m2/year, respectively; p < 0.001). How-
ever, the proportion of patients with significant weight 
loss did not differ between the ACEis and olmesartan 
groups (3.2% vs. 2.0%, respectively; p = 0.224). The de-
crease of total cholesterol is higher in ACEi than olme-
sartan group (–7.8 mg/dL/year vs. –3.4 mg/dL/year, re-
spectively; p < 0.001).
DISCUSSION
Our nationwide cohort study found that olmesartan use 
was not associated with a higher incidence of intestinal 
Table 4. Changes of clinical and biochemical parameters during drug use among matched cohort
Variable ACEi (n = 665) Olmesartan (n = 665) p value
Age, yr 61.5 ± 11.5 61.0 ± 10.5 0.658
Female sex 210 (31.6) 211 (31.7) 1.000
Income level, deciles  6.0 ± 2.4  5.9 ± 2.5 0.658
Initial examination time, yr 2,006.7 ± 2.1 2,006.7 ± 2.0 0.979
Follow-up duration, yr  2.4 ± 0.8  2.3 ± 0.8 0.614
Comorbidities 
Hypertension 561 (84.4) 573 (86.2) 0.395
Dyslipidemia 269 (40.5) 274 (41.2) 0.823
Heart failure 56 (8.4) 56 (8.4) 1.000
Dementia 5 (0.8) 7 (1.1) 0.772
Diabetes mellitus 224 (33.7) 205 (30.8) 0.291
Autoimmune disease 11 (1.7) 13 (2.0) 0.837
Organ transplantation 2 (0.3) 0 0.479
Ongoing cancer 20 (3.0) 22 (3.3) 0.875
Chronic kidney disease 6 (0.9) 6 (0.9) 1.000
Systolic blood pressure
Baseline, mmHg 134.9 ± 17.9 135.0 ± 16.5 0.875
Change, mmHg/yr –2.9 ± 8.8 –2.6 ± 9.6 0.605
Weight
Baseline, kg 65.8 ± 11.2 66.5 ± 11.2 0.272
Change, kg/yr –0.3 ± 1.6  0.1 ± 1.4 < 0.001
Significant weight lossa 21 (3.2) 13 (2.0) 0.224
Body mass index
Baseline, kg/m2 24.9 ± 3.0 24.9 ± 3.1 0.870
Change, kg/m2/yr –0.1 ± 0.6  0.0 ± 0.6 < 0.001
Total cholesterol
Baseline, mg/dL 201.5 ± 39.0 201.4 ± 38.7 0.961
Change, mg/dL/yr –7.8 ± 21.2 –3.4 ± 19.4 < 0.001
Hemoglobin
Baseline, g/dL 14.4 ± 1.5 14.4 ± 1.5 0.534
Change, g/dL/yr –0.2 ± 0.6 –0.2 ± 0.6 0.115
Values are presented as mean ± SD or number (%).
ACEi, angiotensin converting enzyme inhibitor.
aSignificant weight loss was defined as more than 5% loss of body weight compared with baseline
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malabsorption than ACEis or other ARBs in Koreans. 
The subgroup comparisons of clinical and biochemical 
parameters before initiation and during drug use re-
vealed that decrease of BMI or weight loss is more ap-
parent in ACEis group than in olmesartan group. The 
risk of decrease in cholesterol levels, which is a feature 
of celiac disease, was not evident in patients using olme-
sartan, either. 
Following the study of Rubio-Tapia et al. [2], which 
suggested an association between olmesartan and sprue-
like enteropathy of unknown causes, several similar cas-
es have been reported. Ianiro et al. [14] identified several 
shared symptoms and disease courses in patients sus-
pected to have olmesartan-associated enteropathy. Most 
cases were old Caucasians who had been exposed to 
olmesartan for more than 6 months. A gluten-free diet 
did not improve the symptoms in the most patients; 
however, the symptoms resolved following the cessa-
tion of olmesartan. Moreover, several cases of profound 
sprue-like enteropathy associated with other ARBs have 
been reported [5,6]. 
A national survey conducted in France studied 36 pa-
tients suspected to have olmesartan-associated enterop-
athy [15]. Although the study did not include a deliberate 
rechallenge test, interruption of the drug was followed 
by remission, and reintroduction of the drug resulted in 
relapse. In the study using the French National Health 
Insurance Claim database, Basson et al. [8] found that 
olmesartan was associated with an increased risk of 
hospitalization for intestinal malabsorption and celiac 
disease. The risk of enteropathy was higher in patients 
with a longer duration of treatment. However, accord-
ing to the Naranjo probability scale, a cause-effect re-
lationship is only probable because none  of patients 
with suspected olmesartan-associated enteropathy was 
exposed to a rechallenge test [16]. Following a search of 
the Mayo Clinic endoscopy database, Greywoode et al. 
[17] concluded that olmesartan-associated enteropathy is 
a rare adverse drug effect, and that milder presentations 
causing diarrhea in a substantial number of outpatients 
are unlikely. The large randomized clinical trial found 
no significant differences in the rate of gastroentero-
logical adverse events and diarrhea between olmesartan 
and placebo groups with DM [18]. The cohort study us-
ing a United States integrated insurance and laboratory 
claim database found no difference in olmesartan- and 
other ARB-associated hospital admissions in patients 
with DM, either [19]. The mechanisms underlying the 
putative association between olmesartan and sprue-
like enteropathy are not known. Previous case reports 
have shown that symptoms appear months to years after 
olmesartan initiation. Intestinal biopsies have revealed 
that villous atrophy and mucosal inflammation im-
prove after drug discontinuation, but are not affected by 
a gluten-free diet. Moreover, IgA transglutaminase an-
tibodies are notably absent. A cell-mediated or delayed 
hypersensitivity reaction, potentially associated with the 
human leukocyte antigen-DQ cell surface receptor type 
2, has been proposed [2]. The HLA-DQ2 or HLA-DQ8 
haplotype is present in 70% of reported patients [3]. The 
fact that the prevalence of DQ2/DQ8 is estimated to be 
30% to 40% in normal Western populations [20] and 
that reported cases have a higher prevalence of a sus-
ceptible genetic background for celiac disease, suggests 
a possible role for genetics in olmesartan-induced en-
teropathy. 
The actual prevalence of celiac disease in Northeast 
Asia, including Korea and Japan, is not known. To date, 
celiac disease has only been described in two case reports 
in Korea [21,22]. One reason for the low prevalence of ce-
liac disease is the low prevalence of HLA DQ2/DQ8 hap-
lotypes in these countries. In contrast to the relatively 
high prevalence of the haplotypes in Western countries 
and India (more than 20%), the prevalence of the hap-
lotypes is less than 5% in Japan and Korea [9]. Variance 
in the HLA DQ2 and DQ8 haplotypes among countries 
may explain geographic differences in olmesartan-as-
sociated enteropathy. However, possible adverse effects 
induced by olmesartan should not be overlooked. Al-
though our findings suggest that there is no association 
between olmesartan and the incidence of enteropathy 
in the Korean population, awareness of olmesartan-as-
sociated enteropathy may help physicians to avoid mis-
classification of the disorder, and once identified, the 
intervention (switching antihypertensive medication) is 
simple and effective.
The reason why enteropathy was more prevalent in 
patients using ACEi than patients using ARBs is not 
clear. This result should be interpreted with caution 
due to a relatively small number of patients developing 
intestinal malabsorption. Patients using ACEi had more 
DM, heart failure, autoimmune disease, history of or-
8 www.kjim.org
The Korean Journal of Internal Medicine. 2017 Nov 27. [Epub ahead of print]
https://doi.org/10.3904/kjim.2017.002
gan transplantation and ongoing cancer compared with 
those using olmesartan. Although we adjusted all these 
comorbidities and income levels, our findings may re-
sult from differences in baseline characteristics which 
were not adjusted. In order to more accurately correct 
baseline characteristics, we performed additional anal-
ysis with propensity score matching of various results 
from health examination. In this analysis, we also found 
that body weight was more decreased in ACEi group. 
However, there was no difference in significant body 
weight loss, which might affect the prognosis in el-
derlies [12]. Further researcher is needed on antihyper-
tensive medication and subclinical weight changes in 
Asians.
The strength of this study is the first to identify the 
relationship between olmesartan and intestinal malab-
sorption in Asians by analyzing nationally representa-
tive cohort with relatively large sample size and long fol-
low-up duration. The limitations of our study include 
the observational nature of the study design and our 
inability to access complete medical records. Because 
we used NHIS claim data, it is likely that missing diag-
noses or misclassification of intestinal malabsorption or 
other comorbidities occurred as a result of diagnostic or 
coding errors, which could cause misinterpretation of 
the adverse drug effects. Celiac disease is rare in Korea; 
thus, it may have been underdiagnosed in our sample. 
Furthermore, milder presentations of drug-associated 
enteropathy may have been overlooked by physicians 
and patients. We tried to correct these errors by com-
paring body weight, hemoglobin, and cholesterol in the 
drug groups, which can be affected by hidden intesti-
nal malabsorption [23]. The NHIS-NSC 2002 to 2013 is a 
random sample of 2% of the general Korean population. 
Although this national cohort is a relatively small pro-
portion of the population, it represents a stratified ran-
dom sample of the Korean population with a long-term 
follow up. Further prospective larger-scale studies are 
required to investigate olmesartan-associated enterop-
athy and other adverse effects in Asians.
In conclusions, we found no evidence to suggest that 
olmesartan is associated with intestinal malabsorption 
or significant body weight loss in the general Korean 
population. 
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